argentin
hemorrhag
fever
ahf
rodentborn
ill
caus
arenaviru
junin
endem
humid
pampa
argentina
ahf
signific
morbid
sinc
emerg
casefat
rate
ill
without
treatment
use
live
attenu
vaccin
markedli
reduc
incid
ahf
present
specif
therapi
involv
transfus
immun
plasma
defin
dose
neutral
antibodi
prodrom
phase
ill
howev
altern
form
treatment
call
due
current
difficulti
earli
detect
ahf
relat
decreas
incid
troubl
maintain
adequ
stock
immun
plasma
absenc
effect
therapi
sever
ill
patient
progress
neurologichemorrhag
phase
ribavirin
might
substitut
immun
plasma
provid
suppli
guarante
immun
immunoglobulin
monoclon
antibodi
also
consid
new
therapeut
option
develop
system
inflammatori
syndrom
also
valuat
sever
form
ahf
argentin
hemorrhag
fever
ahf
sever
viral
hemorrhag
fever
endem
fertil
farm
plain
central
argentina
humid
pampa
fig
maiztegui
junin
viru
famili
arenavirida
etiolog
agent
ahf
rodentborn
viru
calomi
musculinu
identifi
princip
reservoir
human
exposur
junin
viru
believ
occur
inhal
aerosol
bodi
fluid
excret
infect
rodent
typic
agricultur
work
emerg
ahf
hypothes
result
human
alter
habitat
relat
agricultur
practic
chang
environ
report
favor
popul
growth
c
musculinu
sinc
recognit
ill
annual
outbreak
regist
without
interrupt
number
case
approxim
avail
effect
live
attenu
junin
viru
vaccin
consist
reduct
correspond
author
tel
fax
email
address
direccioninevh
speedycomar
da
enria
incid
ahf
achiev
enria
barrera
oro
enria
et
al
object
articl
review
knowledg
acquir
treatment
ill
discuss
futur
expect
incub
period
usual
day
infect
junin
viru
result
clinic
diseas
three
phase
recogn
ill
prodrom
neurologicalhemorrhag
convalesc
enria
et
al
prodrom
phase
phase
last
first
week
onset
symptom
onset
insidi
chill
malais
anorexia
headach
myalgia
center
particularli
lower
back
moder
hyperthermia
c
common
symptom
includ
retroorbit
pain
nausea
vomit
epigastr
pain
photophobia
dizzi
constip
mild
diarrhea
physic
examin
reveal
flush
face
neck
upper
chest
conjunctiv
congest
periorbit
edema
gum
look
congest
may
bleed
spontan
slight
pressur
soft
palat
enanthem
repres
petechia
small
vesicl
almost
constantli
found
typic
patient
cutan
petechia
axillari
region
upper
chest
arm
lymph
node
laterocerv
region
enlarg
gener
sign
pulmonari
abnorm
detect
rel
bradycardia
orthostat
hypotens
frequent
found
hepatomegali
splenomegali
jaundic
rare
end
phase
patient
may
irrit
letharg
fine
tremor
hand
tongu
moder
ataxia
cutan
hyperesthesia
decreas
deep
tendon
reflex
muscular
tonic
present
femal
presenc
metrorrhagia
characterist
superimpos
oral
candidiasi
frequent
found
end
phase
neurologichemorrhag
phase
around
case
ahf
day
onset
symptom
enter
phase
present
sever
hemorrhag
neurolog
manifest
shock
superimpos
bacteri
infect
hemorrhag
sign
includ
hematemesi
melena
hemoptysi
epistaxi
hematoma
metrorrhagia
hematuria
neurolog
involv
begin
mental
confus
mark
ataxia
increas
irrit
tremor
follow
delirium
gener
convuls
coma
superimpos
bacteri
infect
present
pneumonia
septicemia
may
complic
diseas
period
acut
renal
failur
uncommon
may
appear
phase
termin
case
usual
prolong
period
shock
consequ
acut
tubular
necrosi
convalesc
phase
surviv
case
experi
prolong
protract
convalesc
last
month
patient
experi
asthenia
irrit
memori
chang
hair
loss
around
case
treat
immun
plasma
develop
late
neurolog
syndrom
ln
ln
begin
period
free
symptom
character
febril
symptom
cerebellar
sign
cranial
nerv
palsi
enria
et
al
enria
case
ln
regist
among
ahf
patient
recov
without
specif
treatment
enria
et
al
singl
case
observ
patient
treat
late
cours
ill
intraven
ribavirin
enria
et
al
clinic
laboratori
studi
first
week
ill
progress
leucopenia
thrombocytopenia
count
around
white
cell
platelet
per
mm
sediment
rate
normal
decreas
proteinuria
urinari
sediment
contain
hyalinegranular
cast
red
blood
cell
elev
aspart
transaminas
ast
creatin
phosphokinas
cpk
lactat
dehydrogenas
ldh
common
mild
serum
creatinin
urea
gener
normal
increas
sever
case
proport
dehydr
shock
acut
ill
cerebrospin
fluid
csf
normal
even
patient
sever
neurolog
form
howev
csf
patient
ln
show
moder
increas
number
cell
normal
sugar
normal
moder
increas
number
cell
presenc
antibodi
junin
viru
titer
exceed
ratio
compar
serum
enria
et
al
enria
note
case
ahf
believ
result
inhal
viruscontain
materi
infect
rodent
viral
replic
thought
occur
initi
site
infect
gener
lung
subsequ
dissemin
parenchym
tissu
wide
varieti
organ
may
affect
includ
vascular
endothelium
myocardium
kidney
central
nervou
system
buchmeier
et
al
gross
patholog
chang
gener
nonspecif
maiztegui
bleed
seen
ahf
consid
result
thrombocytopenia
abnorm
platelet
function
induc
plasma
compon
alter
blood
coagul
fibrinolysi
activ
marta
et
al
haemostat
abnorm
includ
prolong
activ
partial
thromboplastin
time
aptt
low
level
factor
viii
ix
increas
valu
factor
v
von
willebrand
factor
fibrinogen
decreas
antithrombin
iii
plasminogen
endotheli
cell
involv
shown
increas
level
von
willebrand
factor
heller
et
al
ahf
viremia
present
throughout
acut
febril
period
high
titer
endogen
demonstr
accompani
viremia
levi
et
al
level
decreas
transfus
immun
plasma
tumor
necrosi
titer
also
increas
heller
et
al
prodrom
neurologicalhemorrhag
phase
acut
transitori
immunodefici
demonstr
delay
humor
respons
depress
cellmedi
immun
return
normal
valu
earli
convalesc
enria
et
al
enria
et
al
vallejo
et
al
laboratorybr
mice
rat
guinea
pig
nonhuman
primat
infect
experiment
junin
viru
given
use
data
understand
pathogen
process
ahf
boxaca
et
al
green
et
al
kenyon
et
al
mckee
et
al
mckee
et
al
guinea
pig
reproduc
human
lesion
increas
viraemia
day
postinfect
death
around
day
infect
guinea
pig
develop
leucopenia
thrombocytopenia
reproduc
hemorrhag
manifest
ahf
die
without
detect
antibodi
model
immun
serum
treatment
decreas
mortal
administr
day
day
infect
anim
treat
day
infect
mortal
modifi
die
without
classic
hemorrhag
manifest
ill
weissenbach
et
al
anim
model
infect
junin
viru
treat
pool
homolog
immun
serum
titer
antibodi
measur
therapeut
unit
immun
sera
sera
prevent
sign
ill
administ
h
infect
also
prevent
ill
death
late
day
infect
amount
therapeut
unit
increas
kenyon
et
al
surviv
anim
develop
late
neurolog
syndrom
promin
hindlimb
paralysi
kenyon
et
al
treatment
guinea
pig
ribavirin
tributylribavirin
reduc
mortal
although
viral
replic
delay
mean
time
death
prolong
kenyon
et
al
junin
viru
infect
rhesu
monkey
marmoset
produc
lesion
similar
report
human
case
ahf
mckee
et
al
common
find
includ
hemorrhag
bone
marrow
necrosi
mild
hepatocellular
necrosi
poliencephalomyel
autonom
glanglioneur
callithrix
jacchu
infect
junin
viru
develop
acut
hematolog
neurolog
manifest
anemia
leucopenia
thrombocytopenia
die
within
day
inocul
without
demonstr
antijunin
antibodi
immun
serum
treatment
junin
virusinfect
marmoset
found
reduc
mortal
viraemia
viral
titer
organ
lower
late
neurolog
sign
appear
treat
survivor
weissenbach
et
al
b
avila
et
al
treatment
junin
viru
infect
c
jacchu
antivir
ribavirin
result
increas
surviv
rate
delay
mean
day
death
rhesu
macaqu
infect
differ
strain
junin
viru
obtain
human
differ
clinic
form
ahf
develop
anorexia
lassitud
gastrointestin
disturb
vascular
phenomena
second
week
inocul
late
diseas
pattern
induc
strain
analog
seen
human
deriv
green
et
al
prophylact
therapeut
treatment
junin
viru
infect
rhesu
macaqu
ribavirin
prove
use
modifi
initi
cours
ill
although
survivor
develop
lateonset
central
nervou
system
ill
death
mckee
et
al
histor
aspect
end
sever
viral
human
infect
treat
either
immun
sera
gamma
globulin
obtain
use
base
benefici
effect
obtain
either
prevent
develop
ill
decreas
sever
diseas
prevent
develop
complic
accord
time
administ
gross
et
al
rinaldo
ahf
almost
sinc
discoveri
junin
viru
plasma
come
person
ahf
clinic
ground
use
therapeut
measur
empir
use
base
advantag
result
report
hepat
rubella
poliomyel
mump
measl
result
obtain
report
satisfactori
attempt
measur
efficaci
benefici
effect
form
treatment
consid
inconclus
reason
placebocontrol
trial
design
ruggiero
et
al
ruggiero
et
al
doubl
blind
trial
immun
plasma
doubl
blind
placebocontrol
studi
perform
among
patient
clinic
diagnosi
ahf
hospit
pergamino
less
day
onset
symptom
patient
randomli
alloc
receiv
intraven
either
ml
immun
plasma
normal
plasma
ultim
case
laboratori
confirm
infect
junin
viru
enter
trial
casefat
rate
among
case
treat
normal
plasma
rate
patient
treat
immun
plasma
public
health
action
reduc
afh
casefat
rate
demonstr
efficaci
immun
plasma
nation
program
control
ahf
develop
program
endors
earli
use
immun
plasma
patient
clinic
diagnosi
ahf
standard
specif
treatment
ill
immun
plasma
bank
avail
unit
certifi
qualiti
establish
around
ahf
endem
area
treatment
effect
transfus
first
week
ill
enria
maiztegui
intens
train
program
among
physician
nurs
endem
area
develop
order
accomplish
earli
clinic
diagnosi
requir
done
conjunct
comprehens
activ
educ
health
affect
commun
object
promot
immedi
medic
consult
presenc
febril
sign
symptom
activ
also
address
encourag
person
surviv
ahf
donat
plasma
standard
dose
immun
plasma
therapeut
dose
immun
plasma
ml
origin
establish
empir
benefici
effect
treatment
attribut
mainli
specif
action
neutral
antibodi
junin
viru
viremia
shown
reduc
ahf
patient
transfus
immun
plasma
montardit
et
al
till
begin
complement
fixat
indirect
immunofluoresc
method
use
serolog
diagnosi
ahf
select
immun
plasma
donor
becam
possibl
standard
plaqu
neutral
assay
cell
cultur
found
titer
vari
wide
peopl
ahf
hand
correl
among
titer
complement
fixat
immunofluoresc
neutral
antibodi
individu
sera
decid
determin
whether
low
dose
neutral
antibodi
associ
higher
mortal
defin
therapeut
dose
immun
plasma
basi
quantiti
neutral
antibodi
given
therapeut
unit
neutral
antibodi
calcul
bodi
weight
patient
weight
titer
neutral
antibodi
unit
immun
plasma
given
first
retrospect
studi
shown
lower
dose
neutral
antibodi
associ
higher
mortal
prospect
studi
dose
immun
plasma
establish
tukg
neutral
antibodi
per
kg
bodi
weight
enria
et
al
effect
immun
plasma
treatment
ahf
impact
institut
immun
plasma
specif
ahf
treatment
shown
decreas
casefat
rate
howev
coincid
mark
decreas
incid
ill
due
vaccin
candid
vaccin
increas
casefat
rate
ahf
regist
fig
attribut
failur
time
recognit
earli
sign
ill
among
popul
health
care
worker
due
declin
morbid
argument
give
rational
evalu
altern
form
treatment
ahf
lack
efficaci
immun
plasma
patient
day
evolut
enria
maiztegui
risk
transfusionborn
diseas
saavedra
et
al
present
late
neurolog
syndrom
around
treat
ahf
survivor
enria
et
al
enria
difficulti
mainten
adequ
stock
immun
plasma
consid
suitabl
antivir
test
ahf
case
accord
vitro
test
preclin
studi
huggin
et
al
et
al
consid
alreadi
effect
treatment
clinic
trial
human
volunt
origin
perform
ahf
case
day
onset
symptom
enria
et
al
enria
maiztegui
studi
done
two
phase
first
open
studi
patient
receiv
ribavirin
second
doubl
blind
trial
case
receiv
ribavirin
placebo
ribavirin
viratek
costa
mesa
california
given
intraven
accord
follow
schedul
mgkg
load
dose
follow
mgkg
everi
h
day
mgkg
everi
h
follow
day
ultim
patient
diagnosi
ahf
confirm
receiv
ribavirin
die
casefat
rate
tabl
although
ribavirin
treatment
abl
demonstr
signific
reduct
mortal
result
indic
drug
antivir
effect
advanc
case
ahf
includ
clearanc
viraemia
observ
case
day
initi
treatment
drop
endogen
ifn
titer
observ
day
first
dose
drug
delay
time
death
patient
die
advers
effect
observ
ribavirintr
ahf
patient
develop
anemia
event
previous
document
among
secondari
reaction
drug
shulman
hand
survivor
treat
ribavirin
develop
earli
convalesc
febril
syndrom
alter
csf
abnorm
evok
respons
similar
one
describ
ahf
patient
treat
immun
plasma
ln
cristiano
et
al
enria
find
suggest
treatment
ribavirin
ahf
might
expect
result
case
untoward
effect
similar
produc
immun
plasma
treatment
result
obtain
clinic
trial
argu
favor
possibl
benefici
effect
ribavirin
ahf
consid
lack
efficaci
observ
trial
could
attribut
late
initi
treatment
reason
protocol
earli
use
ribavirin
ahf
case
develop
preliminari
phase
case
less
day
evolut
would
includ
patient
would
receiv
ribavirin
day
upon
finish
treatment
would
also
receiv
transfus
immun
plasma
earli
enough
effect
given
case
would
receiv
within
day
onset
symptom
although
protocol
approv
patient
includ
due
problem
obtain
adequ
continu
suppli
drug
anoth
point
consid
high
cost
treatment
junin
viru
well
south
american
pathogen
arenavirus
includ
nation
institut
allergi
infecti
diseas
niaid
among
categori
agent
could
weapon
bioterrorist
reason
hemorrhag
fever
arenavir
origin
consid
prioriti
biodefens
program
project
develop
new
antivir
drug
potenti
inclus
strateg
stockpil
initi
result
product
might
deserv
evalu
treatment
ahf
ifn
unnatur
occur
bioengin
approv
treatment
chronic
hepat
c
activ
pichind
tacarib
virus
cell
cultur
hamster
model
pichind
viru
infect
interferon
treatment
significantli
protect
anim
death
prolong
surviv
die
reduc
viru
titer
limit
liver
damag
furthermor
interferon
also
show
efficaci
initi
treatment
delay
day
infect
gowen
et
al
combin
therapi
ribavirin
ifn
treatment
pichind
infect
hamster
result
synergist
activ
combin
therapi
reduc
effect
dose
ribavirin
would
serv
limit
toxic
gowen
et
al
highthroughput
screen
identif
small
molecul
inhibitor
small
molecul
compound
screen
tacarib
virusinduc
cytopath
effect
assay
compound
name
chosen
drug
develop
demonstr
protect
antivir
efficaci
tacarib
mous
challeng
model
bolken
et
al
thepyrazin
deriv
also
show
efficaci
treat
pichind
infect
hamster
gowen
et
al
administr
decay
thiaptam
pichindeinfect
guinea
pig
result
signific
reduct
mortal
enhanc
guinea
pig
macrophag
fennewald
et
al
among
antiretrovir
znfinger
activ
compound
screen
vitro
junin
viru
three
show
antivir
activ
aromat
disulphid
consid
potent
virucid
agent
et
al
instituto
de
hemoderivado
de
belong
universidad
nacion
de
argentina
produc
immun
immunoglobulin
intramuscular
use
deriv
immun
plasma
obtain
inevh
never
use
clinic
trial
consid
therapeut
effect
immunoglobulin
given
intraven
hand
intramuscular
inject
contraind
viral
hemorrhag
fever
project
produc
immun
immunoglobulin
intraven
use
develop
avail
methodolog
immunoglobulin
depart
volum
plasma
possibl
obtain
case
ahf
due
low
incid
diseas
restrict
endem
geograph
area
reason
modif
new
develop
requir
product
would
orphan
one
without
commerci
revenu
special
fund
requir
initi
activ
product
avail
far
preclin
studi
object
develop
monoclon
antibodi
therapeut
use
substrat
peripher
lymphocyt
bone
narrow
specimen
ahf
convalesc
select
basi
titer
neutral
antibodi
junin
viru
differ
project
initi
far
yield
product
initi
anim
studi
although
ahf
alreadi
effect
treatment
reduc
mortal
effect
vaccin
reduc
morbid
would
still
need
better
therapeut
option
expect
even
adequ
vaccin
coverag
ahf
case
could
occur
case
per
year
distribut
three
main
site
recognit
ill
physician
wors
also
expect
would
frequent
see
sever
form
avail
drug
broad
antivir
spectrum
would
welcom
evalu
simultan
agent
effect
therapi
among
differenti
diagnosi
ahf
rational
appli
drug
develop
treatment
system
inflammatori
disord
immun
plasma
specif
therapi
success
use
ahf
success
strongli
link
fact
epidem
involv
case
regist
everi
year
restrict
endem
area
mostli
rural
avail
effect
live
attenu
junin
viru
vaccin
candid
mark
reduct
incid
ahf
achiev
fig
hand
new
geograph
extens
endem
area
regist
last
decad
involv
surround
big
citi
rosario
inhabit
new
situat
earli
recognit
ahf
accord
algorithm
propos
nation
program
ahf
control
oper
fig
ahf
diagnosi
establish
frequent
late
cours
ill
smaller
number
patient
result
increas
casefat
rate
fig
reduct
diseas
incid
also
herald
futur
problem
avail
plasma
donor
although
plasma
candid
vaccine
use
altern
sourc
neutral
antibodi
titer
vaccine
much
lower
convalesc
ill
enria
barrera
oro
one
puzzl
secondari
event
associ
treatment
immun
plasma
ln
first
descript
ahf
recogn
patient
could
present
neurolog
diseas
acut
phase
ill
diseas
known
among
inhabit
endem
area
relaps
entiti
name
late
neurolog
syndrom
ahf
sever
physiopathogen
mechan
suggest
explain
ln
humor
immun
respons
differ
patient
ln
present
delay
primari
respons
case
treat
immun
plasma
achiev
higher
titer
neutral
antibodi
junin
viru
surviv
case
even
receiv
immun
plasma
ratio
antibodi
titer
pair
serum
csf
sampl
may
suggest
local
synthesi
antibodi
enria
et
al
search
junin
viru
isol
attempt
even
cocultiv
rtpcr
blood
lymphoid
tissu
csf
consist
neg
higher
titer
neutral
antibodi
csfserum
antibodi
ratio
ln
case
suggest
possibl
prolong
antigen
stimul
probabl
longer
persist
viru
antigen
central
nervou
system
one
case
ln
observ
among
ahf
case
treat
ribavirin
neither
ribavirin
immun
plasma
cross
bloodbrain
barrier
argu
ln
produc
viru
alreadi
establish
central
nervou
system
although
interv
free
symptom
led
consider
ln
postinfecti
encephalomyel
absenc
lesion
white
matter
shown
magnet
reson
imag
rule
possibl
cristiano
et
al
enria
ahf
case
occur
outsid
argentina
either
result
travel
hospit
outsid
countri
consequ
bioterror
attack
ahf
immun
plasma
would
probabl
readili
avail
furthermor
usa
european
countri
possibl
therapi
would
find
resist
safeti
regulatori
andor
medic
legal
concern
case
ribavirin
would
probabl
use
empir
mani
consider
argu
explor
substitut
treatment
patient
day
evolut
antiinflammatori
respons
failur
adapt
immun
consid
lead
termin
state
immun
paralysi
bracco
et
al
molina
maiztegui
enria
et
al
enria
et
al
levi
et
al
vallejo
et
al
marta
et
al
marta
et
al
elucid
common
pathogenet
mechan
infecti
system
inflammatori
syndrom
might
lead
new
treatment
possibl
bray
alreadi
suitabl
anim
model
perform
preclin
studi
would
also
possibl
perform
clinic
studi
ahf
erad
even
good
vaccin
coverag
isol
case
small
outbreak
expect
continu
howev
recruit
volunt
would
easi
continu
promin
outbreak
allow
perform
clinic
trial
current
specif
treatment
ahf
consist
earli
transfus
immun
plasma
standard
dose
neutral
antibodi
altern
form
treatment
requir
given
difficulti
maintain
suffici
stock
immun
plasma
possibl
advers
event
hand
new
treatment
sever
case
evolv
hemorrhag
andor
neurolog
form
ill
also
need
suitabl
anim
model
would
possibl
perform
clinic
trial
new
product
develop
ribavirin
may
prove
use
ahf
treatment
provid
drug
initi
earli
cours
ill
guarante
continu
suppli
drug
reduct
cost
consid
evalu
clinic
trial
